

Resource Summary Report

Generated by [dkNET](#) on Sep 17, 2026

Purified anti-human CD28

RRID:AB_314304

Type: Antibody

Proper Citation

BioLegend Cat# 302902, RRID:AB_314304

Antibody Information

URL: http://antibodyregistry.org/AB_314304

Proper Citation: BioLegend Cat# 302902, RRID:AB_314304

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F, Costim, FA

Antibody Name: Purified anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_314304

Vendor: BioLegend

Catalog Number: 302902

Alternative Catalog Numbers: 302901

Record Creation Time: 20231110T044958+0000

Record Last Update: 20260829T103312+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD28.

No alerts have been found for Purified anti-human CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Jassowicz L, et al. (2026) Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes. Cancer cell, 44(6), 1290.

Kocher K, et al. (2026) Integrating complementary approaches reveals antigen-reactive CD4+ T cell states after SARS-CoV-2 vaccination. iScience, 29(6), 116175.

Sohal IS, et al. (2026) Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer. bioRxiv : the preprint server for biology.

Kang E, et al. (2026) Creatine uptake promotes dendritic cell activation and enhances antitumor immunity. iScience, 29(4), 115436.

Crain CR, et al. (2026) Expansion of stemlike HIV-specific CD8+ T cells and limited viral epitope diversity characterize durable posttreatment control of HIV. Science translational medicine, 18(846), eaed0042.

Wang H, et al. (2026) Spatial proximity sequencing maps developmental dynamics in the germinal center. Cell.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. Cell reports, 45(1), 116757.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy. Cell reports. Medicine, 6(9), 102324.

Chen Q, et al. (2025) Systems-level immunomonitoring in children with solid tumors to enable precision medicine. Cell, 188(5), 1425.

Tan Z, et al. (2025) Immune development differs between preterm newborns fed mothers' own milk and donor milk. iScience, 28(7), 112918.

Hahn PA, et al. (2025) Exogenous estrogen enhances T cell activation in male primates. *Cell reports*, 44(9), 116170.

Schmidt KG, et al. (2025) Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naïve people with HIV-1. *iScience*, 28(3), 111949.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Mülling N, et al. (2025) Metabolic profiling of antigen-specific CD8⁺ T cells by spectral flow cytometry. *Cell reports methods*, 5(10), 101185.

Ulutekin C, et al. (2024) B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis. *Cell reports. Medicine*, 5(1), 101351.

Tu X, et al. (2024) S100A9⁺CD14⁺ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. *Journal of experimental & clinical cancer research : CR*, 43(1), 72.

Zhao XJ, et al. (2024) Protocol to evaluate virus-specific CD4⁺ and CD8⁺ T cell responses by spectral flow cytometry. *STAR protocols*, 5(4), 103497.

Zhao XJ, et al. (2024) Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection. *iScience*, 27(7), 110283.

Glass DR, et al. (2024) Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma. *Cell reports. Medicine*, 5(5), 101527.